POMALYST 3 MG
POMALIDOMIDE : 3 MG · DIN 02419602 · BRISTOL-MYERS SQUIBB CANADA
Health Canada status: MARKETED
What is POMALYST?
POMALYST 3 MG contains POMALIDOMIDE : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02419602, held by BRISTOL-MYERS SQUIBB CANADA, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Feb-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is POMALYST used for?
In combination with dexamethasone and bortezomib for multiple myeloma (MM) after ≥1 prior regimen including lenalidomide; or with dexamethasone alone after failure of bortezomib and lenalidomide.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02419602 |
|---|---|
| Brand name | POMALYST |
| Generic / active ingredient | POMALIDOMIDE : 3 MG |
| Manufacturer | BRISTOL-MYERS SQUIBB CANADA |
| Strength | 3 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AX06 POMALIDOMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 03-Feb-2025 |
| Original market date | 2014-02-24 00:00:00 |
How is it administered?
Recommended starting dose: 4 mg orally once daily. Administered in 21-day or 28-day cycles depending on combination regimen. Dose reductions (3 mg, 2 mg, 1 mg) required for toxicities.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard practice is 15-30°C, but text only mentions keeping in blister package).
How is it supplied?
21 count blister packs with aluminum push through foil.
Contraindications
Hypersensitivity to pomalidomide, thalidomide, or lenalidomide; pregnancy and women at risk of becoming pregnant; breast-feeding women; male patients unable to comply with contraceptive measures.
Warnings and precautions
Potential for human birth defects; neutropenia and thrombocytopenia; fatal infections; DVT/PE; hepatotoxicity; anaphylaxis; SJS/TEN/DRESS; tumor lysis syndrome. Available only via RevAid.
What can be used instead?
Other Canadian products sharing ATC code L04AX06 POMALIDOMIDE. 24 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-POMALIDOMIDE | 1 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02520427 |
| APO-POMALIDOMIDE | 2 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02520435 |
| APO-POMALIDOMIDE | 3 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02520443 |
| APO-POMALIDOMIDE | 4 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02520451 |
| JAMP POMALIDOMIDE | 1 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02538059 |
| JAMP POMALIDOMIDE | 2 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02538075 |
| JAMP POMALIDOMIDE | 3 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02538083 |
| JAMP POMALIDOMIDE | 4 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02538091 |
| NAT-POMALIDOMIDE | 1 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02506394 |
| NAT-POMALIDOMIDE | 2 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02506408 |
Who else supplies POMALIDOMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. POMALIDOMIDE appears in 412 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.